企業プロフィール
Arcturus Therapeutics Holdings Inc. 株価・ニュース・カタリスト
- ティッカー:
- ARCT
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
13.21 USD (-3.51%)
終値
最終更新: 2026年10月1日
217M USD
時価総額
株価変動の要因
2026年10月1日 時点で ARCT は 3.51% 下落し、$13.21 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Messenger RNA Medicines Company
Arcturus Therapeutics develops mRNA medicines for respiratory and liver diseases. Its platform combines LUNAR lipid-mediated delivery, STARR self-amplifying RNA technology, and internal drug-substance and drug-product manufacturing expertise.
Inhaled mRNA for Cystic Fibrosis
ARCT-032 is an inhaled mRNA therapy designed to express functional CFTR protein in the lungs of people with cystic fibrosis, including those with Class I mutations who may not respond to current modulators. The program is being evaluated through daily inhaled dosing in a Phase 2 study.
Systemic mRNA for OTC Deficiency
ARCT-810 is an intravenously delivered mRNA therapy intended to restore ornithine transcarbamylase activity in people with OTC deficiency. The Phase 2 program includes adult and pediatric development and is intended to inform an end-of-Phase 2 regulatory path.
Self-Amplifying RNA Vaccine Portfolio
KOSTAIVE is the first approved self-amplifying mRNA COVID-19 vaccine and validates the company's STARR platform. Arcturus has regained global control of KOSTAIVE and a broader infectious-disease portfolio that includes influenza, RSV, and EBV programs, subject to existing regional arrangements.
Manufacturing and Development Partnerships
Arcturus works with Thermo Fisher Scientific on potential Phase 3 development and manufacturing for ARCT-032, with BARDA on pandemic influenza initiatives, and through ARCALIS on Japanese mRNA manufacturing. These relationships extend development capacity without requiring the company to build every capability internally.
今後のカタリスト
- Communication of Phase 2 data and the regulatory plan for ARCT-810 in the third quarter of 2026.
- Decision on advancing ARCT-032 into Phase 3 development in the fourth quarter of 2026.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。